Zim Laboratories Limited — Board Meeting, 20-05-2025: Outcome of Board Meeting

ZIM Laboratories has announced a board meeting on 20 May 2025, approving the audited consolidated financial results for FY2024-25. Revenue edged up to ₹379.03 Cr, while net profit slipped to ₹12.17 Cr from ₹17.25 Cr last year. Operational cash flow remained strong at ₹40.08 Cr despite capex of ₹40.80 Cr. The board appointed Deloitte Haskins & Sells LLP as statutory auditors and BNP & Associates as secretarial auditors for the next five years, subject to shareholder approval. The company continues its steady focus on pharmaceuticals with stable business momentum.